A protein best known for its role in Parkinson’s disease can accelerate Alzheimer’s-related brain changes by up to 20 times in patients who carry elevated levels of both pathologies, according to new research from Mayo Clinic in Rochester, Minn. The finding is especially alarming for women, who appear disproportionately affected by this dual-protein burden. The results challenge a long-standing tendency to treat Alzheimer’s and Parkinson’s as biologically separate conditions and raise urgent questions about how clinicians screen for overlapping brain diseases.
Alpha-Synuclein Speeds Up Tau Buildup
The central finding revolves around alpha-synuclein, a protein that misfolds and clumps in the brains of people with Parkinson’s disease. When researchers detected this protein alongside the amyloid plaques and tau tangles that define Alzheimer’s, the rate of tau accumulation jumped dramatically. A study published in Molecular Neurodegeneration used cerebrospinal fluid (CSF) alpha-synuclein seed amplification assay (SAA) combined with amyloid- and tau-PET imaging to measure how co-pathology influenced disease speed. Patients who tested positive on the SAA, meaning their spinal fluid showed misfolded alpha-synuclein seeding activity, experienced faster amyloid-driven tau accumulation and steeper cognitive decline than those without the protein.
Tau accumulation is the biological step most closely tied to memory loss and functional impairment in Alzheimer’s. Amyloid plaques can sit in the brain for years before symptoms emerge, but once tau begins spreading through cortical regions, decline tends to follow quickly. The presence of alpha-synuclein appears to act as an accelerant in that process, compressing a timeline that might otherwise stretch over a decade into something far shorter. Among patients with Alzheimer’s disease and elevated brain levels of both proteins, brain changes occurred up to 20 times faster, suggesting that alpha-synuclein is not merely a bystander but an active driver of neurodegeneration in the context of Alzheimer’s pathology.
Neuropathological studies have long shown that many older adults harbor multiple misfolded proteins in their brains. Autopsy series catalogued in resources such as the National Institutes of Health database frequently report overlapping deposits of amyloid, tau, alpha-synuclein, and TDP-43. What has been less clear is how these pathologies interact in living patients, and whether one protein can change the trajectory of another. By pairing CSF SAA with serial PET imaging, the Mayo team was able to track that interaction over time and quantify the acceleration effect on tau.
Why Women Face Greater Risk
The sex-specific dimension of the research is what sets it apart from earlier work on mixed-protein pathologies. Mayo Clinic researchers found that women with Alzheimer’s who also tested positive for alpha-synuclein experienced quicker symptom onset and more rapid memory deterioration than men with the same dual burden. In a news release, the Rochester team linked this Parkinson’s-related protein to faster decline in women, emphasizing that female patients with both amyloid-tau pathology and alpha-synuclein seeds deteriorated at a disproportionately high rate.
One plausible biological explanation involves estrogen. Before menopause, estrogen provides a degree of neuroprotection by supporting synaptic plasticity, stabilizing mitochondrial function, and reducing neuroinflammation. After menopause, that protective effect fades, and women often experience a convergence of vascular risk factors, sleep disruption, and immune changes. If alpha-synuclein co-pathology interacts with the loss of estrogen-driven neuroprotection, it could help explain why postmenopausal women with both proteins in their brains deteriorate faster than men of the same age. This hypothesis has not yet been tested in a prospective trial, but the pattern in the Mayo data is consistent enough to warrant sex-stratified follow-up studies using CSF SAA and PET imaging.
Social and clinical factors may compound the biological vulnerability. Women are more likely to live longer, increasing their window of exposure to multiple brain pathologies, and they are also more likely to shoulder caregiving responsibilities that can delay their own evaluation. If clinicians do not routinely consider Parkinson’s-related proteins in women presenting with memory complaints, opportunities to identify high-risk co-pathology early may be missed. The Mayo findings suggest that a one-size-fits-all approach to biomarker testing may be leaving women underserved at the diagnostic stage.
How the Seed Amplification Assay Works
The test at the center of this research, the alpha-synuclein seed amplification assay, detects tiny amounts of misfolded alpha-synuclein in cerebrospinal fluid. A landmark study in the Parkinson’s Progression Markers Initiative (PPMI) cohort, published in The Lancet Neurology, established the assay’s performance across the Parkinson’s disease spectrum and showed that SAA positivity can precede classical motor symptoms like tremor or rigidity. That work demonstrated that the assay is highly sensitive to the abnormal protein seeds that initiate and propagate Lewy body pathology.
The test works by amplifying the misfolding process in a controlled lab setting. A small sample of spinal fluid is incubated with normal alpha-synuclein protein under conditions that favor aggregation. If misfolded seeds are present, they recruit the normal protein into clumps, producing a measurable fluorescent signal as the aggregates form. The result is typically reported as positive or negative, based on predefined thresholds. This binary readout makes SAA attractive for clinical use, though it currently requires a lumbar puncture to obtain the fluid sample, limiting its availability outside specialized centers.
Applying this assay to Alzheimer’s patients, rather than only to those suspected of Parkinson’s, is a relatively new step. A separate longitudinal analysis drawing on the Alzheimer’s Disease Neuroimaging Initiative (ADNI) examined 1,637 participants cross-sectionally and 407 longitudinally. That study, published in Alzheimer’s and Dementia, tracked CSF alpha-synuclein SAA status alongside core Alzheimer’s biomarkers including amyloid-beta 42 and phosphorylated tau 181. Participants who converted from SAA-negative to SAA-positive over time showed accelerated cognitive decline and earlier symptom onset, reinforcing the idea that alpha-synuclein co-pathology is not incidental but actively worsens the Alzheimer trajectory.
Converging Evidence From Multiple Cohorts
The Mayo Clinic findings fit into a broader body of work showing that mixed proteinopathies are the rule rather than the exception in late-life dementia. A recent open-access review of overlapping neurodegenerative pathologies highlights how amyloid, tau, alpha-synuclein, and other misfolded proteins frequently co-occur and may interact synergistically. In that framework, alpha-synuclein is seen as part of a network of misfolding events that can destabilize neuronal circuits once a threshold of combined pathology is crossed.
What distinguishes the new Mayo work is its focus on the tempo of disease and the clear sex difference. By combining CSF SAA with amyloid and tau imaging, the researchers could estimate how quickly tau spread in people with and without alpha-synuclein seeds. The reported up to 20-fold acceleration in some patients, described in the Reuters coverage, underscores that co-pathology is not just a subtle modifier but can fundamentally reshape the course of Alzheimer’s.
These results also dovetail with the ADNI analysis showing that conversion to SAA positivity heralds faster decline, and with the PPMI data indicating that SAA can detect alpha-synuclein misfolding before overt Parkinsonian features emerge. Together, they support a model in which alpha-synuclein pathology can smolder for years, then accelerate tau-driven neurodegeneration once amyloid has primed the brain. In women, that acceleration may be further amplified by hormonal transitions and immune changes around menopause.
Implications for Diagnosis and Treatment
For clinicians, the practical message is that patients with Alzheimer’s symptoms may benefit from broader biomarker panels that include Parkinson’s-related proteins. In memory clinics that already perform amyloid and tau PET scans or CSF testing, adding alpha-synuclein SAA could help identify a subgroup at particularly high risk for rapid progression. Women with early cognitive complaints and a family history of Parkinson’s or Lewy body dementia might be especially strong candidates for such testing.
The findings also have implications for clinical trials. Many Alzheimer’s drug studies enroll participants based on amyloid positivity alone, without systematically assessing other proteinopathies. If alpha-synuclein co-pathology accelerates decline, trials that inadvertently include a high proportion of SAA-positive women could see faster worsening in their placebo groups and potentially confounded treatment effects. Stratifying or adjusting for alpha-synuclein status could sharpen trial readouts and reveal whether certain therapies work better—or worse—in the presence of mixed pathology.
On the treatment front, the data strengthen the case for combination strategies that target more than one misfolded protein. While current anti-amyloid antibodies focus on clearing plaques, future regimens might pair amyloid-lowering agents with drugs aimed at alpha-synuclein aggregation or tau propagation. For high-risk women identified through SAA and imaging, early intervention with such combination approaches could, in theory, slow the otherwise accelerated trajectory highlighted by the Mayo group.
For now, the research leaves patients and families with both a warning and an opportunity. The warning is that overlapping brain diseases can dramatically hasten decline, particularly in women. The opportunity is that increasingly sensitive tools, ranging from CSF seed amplification assays to advanced PET imaging, are beginning to reveal those hidden risks while there is still time to plan care, adjust expectations, and, eventually, tailor treatments to the specific mix of proteins driving each person’s dementia.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
